Show simple item record

dc.contributor.authorCarr, T. H.
dc.contributor.authorAdelman, C.
dc.contributor.authorBarnicle, A.
dc.contributor.authorKozarewa, I.
dc.contributor.authorLuke, S.
dc.contributor.authorLai, Z.
dc.contributor.authorHollis, S.
dc.contributor.authorDougherty, B.
dc.contributor.authorHarrington, E. A.
dc.contributor.authorKang, J.
dc.contributor.authorSaad, F.
dc.contributor.authorSala, N.
dc.contributor.authorThiery-Vuillemin, A.
dc.contributor.authorClarke, Noel W
dc.contributor.authorHodgson, D.
dc.contributor.authorBarrett, J. C.
dc.date.accessioned2022-01-11T12:00:04Z
dc.date.available2022-01-11T12:00:04Z
dc.date.issued2021en
dc.identifier.citationCarr TH, Adelman C, Barnicle A, Kozarewa I, Luke S, Lai Z, et al. Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer Vol. 13, Cancers. MDPI AG; 2021. p. 5830.en
dc.identifier.pmid34830984en
dc.identifier.doi10.3390/cancers13225830en
dc.identifier.urihttp://hdl.handle.net/10541/624949
dc.titleHomologous recombination repair gene mutation characterization by liquid biopsy: a phase II trial of olaparib and abiraterone in metastatic castrate-resistant prostate canceren
dc.typeArticleen
dc.contributor.departmentAstraZeneca, Cambridge CB4 0WG, UKen
dc.identifier.journalCancersen
dc.description.noteen]
refterms.dateFOA2022-04-13T08:00:39Z


Files in this item

Thumbnail
Name:
cancers-13-05830-v2.pdf
Size:
2.216Mb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record